Radical radiotherapy of lung cancer with dose escalation has been associated with increased tumor control. However, these attempts to continually improve local control through dose escalation, have met mixed results culminating in the findings of the RTOG trial 0617, where the heart dose was associated with a worse overall survival, indicating a significant contribution to radiation-induced cardiac morbidity. It is, therefore, very likely that poorly understood cardiac toxicity may have offset any potential improvement in overall survival derived from dose escalation and may be an obstacle that limits disease control and survival of patients. The manifestations of cardiac toxicity are relatively common after high dose radiotherapy of advanced lung cancers and are independently associated with both heart dose and baseline cardiac risk. Toxicity following the treatment may occur earlier than previously thought and, therefore, heart doses should be minimized. In patients with lung cancer, who not only receive substantial heart dose, but are also older with more comorbidities, all cardiac events have the potential to be clinically significant and life-threatening. Sophisticated radiation treatment planning techniques, charged particle therapy, and modern imaging methods in radiotherapy planning, may lead to reduction of the heart dose, which could potentially improve the clinical outcomes in patients with lung cancer. Efforts should be made to minimize heart radiation exposure whenever possible even at doses lower than those generally recommended. Heart doses should be limited as much as possible. A heart dosimetry as a whole is important for patient outcomes, rather than emphasizing just one parameter.

Department of Oncology and Radiotherapy University Hospital in Pilsen alej Svobody 80 304 60 Pilsen Czech Republic

Zobrazit více v PubMed

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. PubMed

Bradley J.D., Paulus R., Komaki R. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–199. PubMed PMC

Majem M., Hernández-Hernández J., Hernando-Trancho F. Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. Clin Transl Oncol. 2019 [Epub ahead of print] PubMed

Machtay M., Bae K., Movsas B. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2012;82(1):425–434. PubMed PMC

Jett J.R., Schild S.E., Kesler K.A., Kalemkerian G.P. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e400S–e419S. PubMed

Kalemkerian G.P. Advances in the treatment of small-cell lung cancer. Semin Respir Crit Care Med. 2011;32(1):94–101. PubMed

Stinchcombe T.E., Gore E.M. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist. 2010;15(2):187–195. PubMed PMC

Bradley J.D., Moughan J., Graham M.V. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys. 2010;77(2):367–372. PubMed PMC

Stinchcombe T.E., Lee C.B., Moore D.T. Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer. J Thorac Oncol. 2008;3(11):1279–1285. PubMed

Socinski M.A., Blackstock A.W., Bogart J.A. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008;26(15):2457–2463. PubMed

Speirs C.K., DeWees T.A., Rehman S. Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer. J Thorac Oncol. 2017;12(2):293–301. PubMed

Roach M.C., Bradley J.D., Robinson C.G. Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer. J Thorac Dis. 2018;10(Suppl 21):S2465–S2473. PubMed PMC

Rodrigues G., Choy H., Bradley J. Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol. 2015;5(3):141–148. PubMed

National Comprehensive Cancer Network. Non-small cell lung cancer guidelines, version 3.2019. PubMed

Postmus P.E., Kerr K.M., Oudkerk M. ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl_4) iv1-iv21. PubMed

Prewett S.L., Aslam S., Williams M.V., Gilligan D. The management of lung cancer: a UK survey of oncologists. Clin Oncol (R Coll Radiol) 2012;24(6):402–409. PubMed

Turrisi A.T., 3rd, Kim K., Blum R. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265–271. PubMed

Miller K.L., Marks L.B., Sibley G.S. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;56(2):355–359. PubMed

https://clinicaltrials.gov/ct2/show/NCT00632853. Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide.

van Nimwegen F.A., Schaapveld M., Janus C.P. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007–1017. PubMed

van Nimwegen F.A., Schaapveld M., Cutter D.J. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34(3):235–243. PubMed

Darby S.C., Cutter D.J., Boerma M. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76(3):656–665. PubMed PMC

Lally B.E., Detterbeck F.C., Geiger A.M. The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2007;110(4):911–917. PubMed

Douillard J.Y., Rosell R., De Lena M., Riggi M., Hurteloup P., Mahe M.A. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys. 2008;72(3):695–701. PubMed

Marks L.B., Yu X., Prosnitz R.G. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005;63(1):214–223. PubMed

Gagliardi G., Constine L.S., Moiseenko V. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S77–85. PubMed

Wang K., Pearlstein K.A., Patchett N.D. Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Radiother Oncol. 2017;125(2):293–300. PubMed PMC

NCI. Common Terminology Criteria for Adverse Events v5.0 NIH publication; 2017.

RTOG. RTOG/EORTC Late Radiation Morbidity Scoring Schema. https://www.rtog.org/ResearchAssociates/AdverseEventReporting.aspx.

Wang K., Eblan M.J., Deal A.M. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol. 2017;35(13):1387–1394. PubMed PMC

Dess R.T., Sun Y., Matuszak M.M. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol. 2017;35(13):1395–1402. PubMed PMC

Tucker S.L., Liu A., Gomez D. Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiother Oncol. 2016;119(3):495–500. PubMed

Schytte T., Hansen O., Stolberg-Rohr T., Brink C. Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer. Acta Oncol. 2010;49(7):1058–1060. PubMed

Janssen-Heijnen M.L., Schipper R.M., Razenberg P.P., Crommelin M.A., Coebergh J.W. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer. 1998;21(2):105–113. PubMed

Wei X., Liu H.H., Tucker S.L. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008;70(3):707–714. PubMed

Marks L.B., Yorke E.D., Jackson A. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–9. PubMed PMC

van den Bogaard V.A., Ta B.D., van der Schaaf A. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. Clin Oncol. 2017;35(11):1171–1178. PubMed PMC

De Ruysscher D., Faivre-Finn C., Moeller D. Lung Group and the Radiation Oncology Group of the European Organization for Research and Treatment of Cancer (EORTC). European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol. 2017;124(1):1–10. PubMed

Movsas B., Hu C., Sloan J. Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the radiation therapy oncology group 0617 randomized clinical trial. JAMA Oncol. 2016;2(3):359–367. PubMed PMC

Wink K.C., Roelofs E., Solberg T. Particle therapy for non-small cell lung tumors: where do we stand? A systematic review of the literature. Front Oncol. 2014;4:292. PubMed PMC

Simone C.B., 2nd, Rengan R. The use of proton therapy in the treatment of lung cancers. Cancer J. 2014;20(6):427–432. PubMed

Giaddui T., Chen W., Yu J. Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC. Radiat Oncol. 2016;11:66. PubMed PMC

Berman A.T., Teo B.K., Dolney D. An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer. Radiat Oncol. 2013;8:144. PubMed PMC

Vojtíšek R., Mužík J., Šlampa P. The impact of PET/CT scanning on the size of target volumes, radiation exposure of organs at risk, TCP and NTCP, in the radiotherapy planning of non-small cell lung cancer. Rep Pract Oncol Radiother. 2014;19:182–190. PubMed PMC

Deniaud-Alexandre E., Touboul E., Lerouge D. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2005;63(5):1432–1441. PubMed

Ren X.C., Liu Y.E., Li J., Lin Q. Progress in image-guided radiotherapy for the treatment of non-small cell lung cancer. World J Radiol. 2019;11(3):46–54. PubMed PMC

Arns A., Blessing M., Fleckenstein J. Towards clinical implementation of ultrafast combined kV-MV CBCT for IGRT of lung cancer : Evaluation of registration accuracy based on phantom study. Strahlenther Onkol. 2016;192(5):312–321. PubMed

Elsayad K., Kriz J., Reinartz G. Cone-beam CT-guided radiotherapy in the management of lung cancer: diagnostic and therapeutic value. Strahlenther Onkol. 2016;192(2):83–91. PubMed

Jiang S.B., Wolfgang J., Mageras G.S. Quality assurance challenges for motion-adaptive radiation therapy: gating, breath holding, and four-dimensional computed tomography. Int J Radiat Oncol Biol Phys. 2008;71(1 Suppl):S103–7. PubMed